IBIO
iBio, Inc.
$0.72
-7.69%
2026-10-23
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-1.94
EPS (TTM)
$-0.32
ROE
-65.7%
Revenue Growth (YoY)
-100.0%
Profit Margin
0.0%
Debt/Equity
2.56
Price/Book
0.77
Beta
1.29
Market Cap
$59.1M
Avg Volume (10D)
704K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.54
60D Low
$0.71
Avg Volume
738K
Latest Close
$0.72
Get breakout alerts for IBIO
Sign up for Breakout Scanner to receive daily notifications when IBIO triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
iBio, Inc. (IBIO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IBIO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IBIO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.